ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis

Kushner, 2009, Circulation, 120, 2271, 10.1161/CIRCULATIONAHA.109.192663 Wright, 2011, J Am Coll Cardiol, 57, 1920, 10.1016/j.jacc.2011.02.009 Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Chen, 2005, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1607, 10.1016/S0140-6736(05)67660-X Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, 1179, 10.1056/NEJMoa050522 Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746 Sibbing, 2010, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement, Circulation, 121, 512, 10.1161/CIRCULATIONAHA.109.885194 Shuldiner, 2009, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, JAMA, 302, 849, 10.1001/jama.2009.1232 Campo, 2010, Poor response to clopidogrel: current and future options for its management, J Thromb Thrombolysis, 30, 319, 10.1007/s11239-010-0457-5 Gros, 1986, Isolation and expression of a complementary DNA that confers multidrug resistance, Nature, 323, 728, 10.1038/323728a0 Fung, 2009, A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function, Biochim Biophys Acta, 1794, 860, 10.1016/j.bbapap.2009.02.014 Taubert, 2006, Impact of P-glycoprotein on clopidogrel absorption, Clin Pharmacol Ther, 80, 486, 10.1016/j.clpt.2006.07.007 Wallentin, 2010, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial, Lancet, 376, 1320, 10.1016/S0140-6736(10)61274-3 Tiroch, 2010, Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events, Am Heart J, 160, 506, 10.1016/j.ahj.2010.06.039 Mega, 2010, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis, Lancet, 376, 1312, 10.1016/S0140-6736(10)61273-1 Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227 Campo, 2011, Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome, J Am Coll Cardiol, 57, 2474, 10.1016/j.jacc.2010.12.047 Spiewak, 2009, Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes, Kardiol Pol, 67, 827 Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4 Aradi, 2010, Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis, Am Heart J, 160, 543, 10.1016/j.ahj.2010.06.004 Verstuyft, 2009, Personalized medicine and antiplatelet therapy: ready for prime time?, Eur Heart J, 30, 1943, 10.1093/eurheartj/ehp295 Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2011, doi:10.1016/j.thromres.2011.07.022. Rideg, 2011, Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention, Pharmacogenomics, 12, 1269, 10.2217/pgs.11.73 Simon, 2011, Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects, Clin Pharmacol Ther, 90, 287, 10.1038/clpt.2011.127 Jeong, 2010, JACC Cardiovasc Interv, 3, 731, 10.1016/j.jcin.2010.05.007 Harmsze, 2010, Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation, Pharmacogenet Genomics, 20, 18, 10.1097/FPC.0b013e328333dafe Mega, 2010, Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis, JAMA, 304, 1821, 10.1001/jama.2010.1543 Harmsze, 2010, CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case–control study, Eur Heart J, 31, 3046, 10.1093/eurheartj/ehq321